Logo image
ROSAH syndrome presenting with recurrent vitreous hemorrhage: a multimodal imaging study
Journal article   Open access   Peer reviewed

ROSAH syndrome presenting with recurrent vitreous hemorrhage: a multimodal imaging study

Rebecca Hong, Tiffany C. S. Lo, Thomas Gordon Campbell, Emily Caruso, Jennifer A. Thompson, Fred K. Chen and Nandini Singh
Ophthalmic Genetics, Vol.46(3), pp.313-317
2025
PMID: 40069099
pdf
ROSAH syndrome presenting with recurrent vitreous hemorrhage a multimodal imaging study4.99 MBDownloadView
Published Version Open Access CC BY V4.0

Abstract

ALPK1 Inherited retinal disease papilledema posterior uveitis macular edema
Background: ROSAH syndrome is an autosomal dominant systemic disease featuring retinal dystrophy, optic nerve edema, splenomegaly, anhidrosis and migrainous headache. Ocular manifestation of ROSAH syndrome can simulate posterior uveitis, vasculitis, generalized retinal dystrophy and neuroretinitis. Purpose: To report a case of a 17-year-old female presenting with recurrent vitreous hemorrhage on a background of dental anomalies and anhidrosis. Materials and Methods: This case report illustrates the clinical findings and multimodal imaging features including spectral domain optical coherence tomography (OCT), OCT angiography (OCTA), fundus autofluorescence (FAF), ultrawide-field Optos fluorescein angiography (FA) and electrophysiology. Results: A retinal dystrophy panel detected the c.710C>T p.Thr237Met variant, confirming genetic diagnosis of ROSAH syndrome. This case further elaborates, by way of multimodal imaging, on two striking features recently described in the literature-preretinal neovascularisation around the disc and along the vascular arcades, as well as an isolated expanding hyperautofluorescent ring around the disc. The use of widefield OCTA complemented the findings of FA in demonstrating the lack of retinal capillary closure. The macular edema was responsive to anti-vascular endothelium growth factor (anti-VEGF) injection, however only for a period of 6-weeks before reoccurrence. Conclusions: This report provides new insights into ROSAH phenotype. Anti-VEGF can be considered as a short-term treatment for ROSAH-associated macular edema.

Details

Metrics

InCites Highlights

These are selected metrics from InCites Benchmarking & Analytics tool, related to this output

Collaboration types
Domestic collaboration
Web Of Science research areas
Genetics & Heredity
Ophthalmology

UN Sustainable Development Goals (SDGs)

This output has contributed to the advancement of the following goals:

#3 Good Health and Well-Being

Source: SDGs from InCites

Logo image